<DOC>
	<DOCNO>NCT02187055</DOCNO>
	<brief_summary>To assess efficacy tofacitinib monotherapy tofacitinib methotrexate compare adalimumab methotrexate . To compare efficacy tofacitinib monotherapy compare tofacitinib combine methotrexate . To compare effect health outcome measure study . To evaluate safety tolerability tofacitinib adalimumab . To evaluate safety zoster vaccine give prior initiation tofacitinb adalimumab .</brief_summary>
	<brief_title>An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Have moderate severe rheumatoid arthritis On methotrexate inadequately controlled Subjects must active tuberculosis inadequately treat tuberculosis infection Subjects must use contraception Subjects previously treat adalimumab Tofacitinib Subjects current malignancy history malignancy , exception adequately treat excised non metastatic basal cell squamous cell cancer skin cervical carcinoma situ . Subjects specific laboratory test abnormality Subjects specific type infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>